Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD4 | P01730 | 10/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988330 | 0.88 | CD4 (0.50) | CD4 | |
| SCHEMBL4986145 | 0.85 | TMEM97 (0.41) | MKNK1AKR1C3CNR1MEN1KMT2A | |
| SCHEMBL4988452 | 0.83 | MEN1 (0.51) | AKR1C3MEN1KMT2AF12 | |
| SCHEMBL4988645 | 0.82 | MAPT (0.42) | MKNK1AKR1C3MEN1KMT2A | |
| SCHEMBL4993378 | 0.80 | KMT2A (0.49) | MKNK1MEN1KMT2A | |
| SCHEMBL4983025 | 0.80 | MEN1 (0.53) | MKNK1MEN1KMT2A | |
| SCHEMBL4982872 | 0.80 | NPC1 (0.39) | F12 | |
| SCHEMBL4986180 | 0.80 | MCOLN3 (0.50) | MEN1KMT2A | |
| SCHEMBL4987016 | 0.80 | PKM (0.51) | MKNK1 | |
| SCHEMBL4992079 | 0.79 | CYP3A4 (0.58) | AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | CD4 2222/4885MKNK1 1672/4885AKR1C3 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.